COVID-19 (Coronavirus) Update: Vaccine Updates | COVID-19 Information | Visitor Guidelines

A Multisite, Phase II Study of Bortezomib, Isatuximab, Cyclophosphamide and Dexamethasone (VICD) Induction in Transplant-Eligible Multiple Myeloma Patients with or without Renal Insufficiency

Protocol No
IIT-DHAKAL-VICD-MM
Principal Investigator
Binod Dhakal
Phase
II
Summary
The purpose of this project is to evaluate if adding another drug, Isatuximab, to a standard induction therapy of Bortezomib, Dexamethasone, and Cyclophosphamide, will help improve the response of patients after receiving subsequent high-dose chemotherapy and ASCT.
Description
Bortezomib, Isatuximab, Cyclophosphamide and Dexamethasone Induction in Transplant-Eligible Multiple
Participating Institutions
Froedtert Hospital
Status
IRB INITIAL APPROVAL